Staphylococcus aureus is a formidable pathogen that escapes killing by immune cells and effectively blocks development of protective antibodies during infection. Coupling these immune evasion mechanisms with increased rates of antibiotic resistance and MRSA is indeed worthy of its title as the superbug.
IMMUNARTES is currently developing vaccines and therapeutics that will effectively neutralize MRSA's immune evasive properties enabling S. aureus infected and/or colonized patients the ability to generate broad protective antibody responses against the pathogen. These vaccine products have proven highly efficacious in multiple animal models of S. aureus disease and IMMUNARTES is eager to test their effectiveness in a clinical setting.
IMMUNARTES is currently developing vaccines and therapeutics that will effectively neutralize MRSA's immune evasive properties enabling S. aureus infected and/or colonized patients the ability to generate broad protective antibody responses against the pathogen. These vaccine products have proven highly efficacious in multiple animal models of S. aureus disease and IMMUNARTES is eager to test their effectiveness in a clinical setting.